Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
In this first part of a three-case series, a 65-year-old man received ruxolitinib for treatment and reported feeling much better after one month, and after two months of treatment, most of his symptoms had completely resolved and his blood cell counts were maintained under control.
Hematology July 5th 2022
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS